Re: Michael S. Hofman, Louise Emmett, Shahneen Sandhu, et al. Overall Survival with [ ¹⁷⁷ Lu]Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-resistant Prostate Cancer (TheraP): Secondary Outcomes of a Randomised, Open-label, Phase 2 Trial. Lancet Oncol 2024;25:99-107.

Autor: Xu J; Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China., Ding L; Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China., Yang B; Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China. Electronic address: yangbnju@gmail.com.

Publikováno v: European urology oncology [Eur Urol Oncol] 2024 Oct; Vol. 7 (5), pp. 1150-1151. Date of Electronic Publication: 2024 Feb 19.

Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol 2022;83:521-33.

Autor: Gandaglia G; Unit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy., Barletta F; Unit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: barletta.francesco@hsr.it., Briganti A; Unit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy., Montorsi F; Unit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Publikováno v: European urology [Eur Urol] 2024 Mar; Vol. 85 (3), pp. e89. Date of Electronic Publication: 2023 Oct 11.

Comparison of quantitative whole body PET parameters on [68Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer

Autor: Narjess Ayati, Lachlan McIntosh, James Buteau, Ramin Alipour, Michal Pudis, Nicholas Daw, Price Jackson, Michael S. Hofman

Publikováno v: Cancer Imaging, Vol 24, Iss 1, Pp 1-8 (2024)

Abstract Background PSMA PET/CT is a predictive and prognostic biomarker for determining response to [177Lu]Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer (mCRPC). Thresholds defined to date may not be generalizable to n

Externí odkaz: https://doaj.org/article/b04bf9cbe61641e8b0c83eb5935c6d9f

Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. Lancet 2020;395:1208-16: PSMA Positron Emission Tomography: One Tracer Fixes Them All!

Autor: Lopci E; Nuclear Medicine Department, Humanitas Clinical and Research Hospital - IRCCS, Rozzano, Italy. Electronic address: egesta.lopci@humanitas.it., Lazzeri M; Urology Department, Humanitas Clinical and Research Hospital - IRCCS, Rozzano, Italy.

Publikováno v: European urology [Eur Urol] 2020 Sep; Vol. 78 (3), pp. e131-e132. Date of Electronic Publication: 2020 Jul 09.

The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer

Autor: Mark S Stein, Victor Kalff, Scott G Williams, Declan G Murphy, Peter G Colman, Michael S Hofman

Publikováno v: Endocrine Oncology, Vol 4, Iss 1, Pp 1-7 (2024)

Objectives: The glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, reduces human prostate cancer incidence, and similar GLP-1 receptor agonists reduce in vitro proliferation and in vivo growth of prostate cancer cell lines. Primary human

Externí odkaz: https://doaj.org/article/2f51d43b92cc4b87931c1374cc70bebc